Earnings ·
Cytokinetics reported second quarter 2026 financial results on August 6, 2026
CYTKCytokinetics Inc
Cytokinetics reported second quarter 2026 financial results on August 6, 2026. Net product revenue for MYQORZO (aficamten) was $25 million, bringing total revenues to $28.6 million compared to $66.8 million in the prior year period which included significant license and milestone payments. The company reported a net loss of $198.8 million, or $(1.50) per share. Cytokinetics raised approximately $760.1 million from a public equity offering at $71.00 per share, increasing its cash position to $1.7 billion as of June 30, 2026. The company updated its full-year 2026 GAAP combined R&D and SG&A expense guidance upward to $860 million–$890 million. Additionally, Cytokinetics announced positive topline results from the ACACIA-HCM Phase 3 trial for non-obstructive HCM and plans to submit a supplemental New Drug Application in Q4 2026. The company operates as a specialty cardiovascular biopharmaceutical firm developing treatments for cardiac muscle dysfunction.